ABOUT ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC)

In Section A, participants will acquire unique doses and schedules of oral ABBV-744 tablet to detect Harmless dosing routine. Further individuals will probably be enrolled in the discovered monotherapy dosign routine. In Phase B, participants will acquire oral ruxolitinib and ABBV-744 is going to be provided as "incorporate-on" therapy. In Phase C,